NO DIFFERENCE IN IMMUNOGENICITY OF THE ORIGINAL AND BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Karin Malíčková  1     Dana Duricova  2     Martin Kolar  2     Martin Bortlík  3     Veronica Hruba     Nadezda Machkova     Katarina Mitrova     Martin Lukas     Milan Lukas    
1 Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic
2 ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech Republic
3 ISCARE I.V.F. a.s., IBD C

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing